Immunoadjuvant treatment of primary grafted and spontaneous AKR-leukemia. I. Treatment efficiency correlated to autoimmune reactivity.
Young AKR mice grafted i.v. with 10(1) or 10(3) cells from spontaneous AKR thymomas were treated with repeated i.v. injections of BCG or subcutaneous injections of irradiated AKR thymoma cells. BCG often cured mice from graft leukemia, whereas the effect of irradiated thymoma cells was less effective. Mice that did not develop graft-leukemia after graft of 10(1) leukemia cells and BCG treatment showed a spontaneous leukemia in 30% of the cases later. Ninety percent of nongrafted mice developed spontaneous leukemia whether BCG-treated or not. General immune reactivity as assessed in individual mice by T and B lymphocyte mitogen tests as well as the hemolytic plaque-forming cell assay had no clear correlation to the effects of immune adjuvants in respect to survival. In contrast, occurrence of self-directed immune reactions were clearly correlated to survival and cure of grafted and BCG-treated mice as revealed by assays both in vitro and in vivo. However, 13 to 25% of the mice apparently cured of leukemia developed a wasting-like syndrome that sometimes terminated in death. The immplications of self-directed immune reactions as mediators of the anti-neoplastic effects of immunoadjuvants.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000920:Antibody-Dependent Cell Cytotoxicity; D001323:Autoantibodies; D001500:BCG Vaccine; D003298:Coombs Test; D005260:Female; D006462:Hemolytic Plaque Technique; D007942:Leukemia, Experimental / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice; D008806:Mice, Inbred AKR; D008807:Mice, Inbred BALB C; D009163:Mycobacterium bovis / Q000276:immunology; D009368:Neoplasm Transplantation; D010835:Phytohemagglutinins / Q000494:pharmacology; D013997:Time Factors
D000276:Adjuvants, Immunologic; D001323:Autoantibodies; D001500:BCG Vaccine; D010835:Phytohemagglutinins